Zacks Investment Research
19 Nov 2026, 16:46 UTC · 2h ago
REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
Impact · against what's priced in
The approval of Livsayis provides a positive catalyst for Regeneron by establishing a new neurology revenue stream, which the market had not yet factored into its growth projections. While the Phase III data supporting the approval was already known, the transition to a commercial product creates a tangible growth vector to offset Eylea erosion.
- REGN+0.50
Not in the price yet
- The price assumes
Whether Regeneron can replace declining Eylea sales
The FDA approval of Livsayis creates a new revenue stream in neurology and the first siRNA product for the company, providing a concrete offset to the 17% decline in Eylea product revenue the market is already tracking.
What REGN's price assumes · Sep 12





